

Provisionally accepted for the publication

**ORIGINAL ARTICLE**

**The impact of antenatal diagnosis of placenta accreta on reducing blood loss: a 57-case monocenter retrospective study**

Short title: The role of antenatal diagnosis of placenta accreta.

Anouar **Jarraya**<sup>1\*</sup>, Manel **Kammoun**<sup>1</sup>, Jed **Hadjkacem**<sup>1</sup>, Yasmine **Ellouze**<sup>1</sup>, Mohamed **Derbel**<sup>2</sup>, Kais **Chaabene**<sup>2</sup>, Kamel **Kolsi**<sup>1</sup>

- 1- Anesthesiology Department, the Hedi Chaker University Hospital, University of Sfax, Tunisia.
- 2- Gynecology and Obstetrics Department, the Hedi Chaker University Hospital, University of Sfax, Tunisia.

**Doi:** 10.36129/jog.2023.120

**\*Corresponding author:** Anouar **Jarraya** PhD. Hedi Chaker University Hospital, El Ain Road Km 0.5 Sfax Tunisia. E-mail : dranouarjarraya1983@gmail.com.

ORCID: 0000-0002-4488-5491.

## ABSTRACT

**Objective.** The aim of our study was to investigate the impact of antenatal diagnosis of PA on blood loss, blood transfusions, and maternal and neonatal morbidity and mortality.

**Materials and Methods.** This is a monocenter retrospective study including all patients who had failed manual removal of the placenta or evidence of placental invasion at the surgery. The patients included were divided into 2 groups:

- Group 1: patients with an antenatal diagnosis according to the ultrasounds or magnetic resonance imaging data.
- Group 2: patients with unexpected placenta accreta.

Then, we compared blood loss estimated by Gross formula, transfusions, and maternal and neonatal morbidity in both groups.

**Results.** In our series, 57 cases of PA were included: 35 patients with antenatal diagnosis (group 1) and 22 with unexpected PA (group 2). The bleeding estimation was  $1610 \pm 908$  ml in group 1 versus  $2480 \pm 1317$  ml in group 2, with  $p = 0.007$ . The need for transfusion was reduced from 95.4 % to 17 % when PA was diagnosed antenatally with  $p = 0.001$ . Unexpected PA was correlated with an increased risk of severe bleeding with OR 2.35; 95%CI 1.08-5.62 and transfusion requirements with OR 1.85; 95%CI: 1.18- 6.1. However, expected PA was correlated with a higher risk of prematurity with OR 2.04, 95%CI 1.05-4.8.

**Conclusions.** The antenatal diagnosis of placenta accreta allowed better maternal outcomes by reducing the blood loss and transfusions requirements. However, it increased the incidence of planned preterm birth.

### Key words

Placenta accreta; antenatal diagnosis; transfusion; blood loss; premature birth

### Introduction:

Placenta accreta is one of the most serious pregnancy complications in which the placenta is abnormally adherent and invades the uterine wall [1]. Its incidence is increasing all over the world following the trend of rising cesarean delivery and intrauterine interventions [2]. Placenta accreta can lead to a life-threatening severe and catastrophic hemorrhage, resulting in hemostatic hysterectomy, blood transfusion, and significant adverse maternal and neonatal outcomes [1].

Ultrasound is the primary tool in antenatal diagnosing placenta accreta, and magnetic resonance imaging is generally performed to help in the diagnosis [3, 4]. Furthermore, the antenatal diagnosis may allow better organization and some precautions that may improve maternal outcomes. The aim of this study was to investigate the role of antenatal diagnosis of placenta accreta and its impact on blood loss, transfusions, and maternal and neonatal morbidity and mortality.

### Methods:

#### a. Study design:

After obtaining patients' oral consent and the approval from the local ethics committee, we conducted a monocenter retrospective study by analyzing the database of patients with

confirmed placenta accreta to assess the impact of the antenatal diagnosis on maternal outcomes and particularly the blood loss and the need for transfusions and neonatal outcomes.

**b. Study setting:**

The study was conducted in the maternity of the Hedi Chaker University Hospital in the region of Sfax in Tunisia. We studied a database of patients who were hospitalized for placenta accreta in the period lasting from January 2016 to March 2021.

**c. Study population with selection criteria:**

We included patients aged from 18 to 45 years old with placenta accreta (where the chorionic villi attach directly to the surface of the myometrium), increta (where the chorionic villi penetrate deeply into the myometrium), and percreta (where chorionic villi penetrate through the uterine serosa). We considered placenta accreta all patients who experienced failed attempts to remove the placenta during the third stage of labor, evidence of placental invasion at surgery and failed manual removal of the placenta partly or totally.

We did not include patients aged less than 18 years, as well as individuals declining to consent or not being able to consent. We did not include patients with suspected placenta accreta but were not confirmed during the delivery (complete placenta removal after delivery). Patients with confirmed placenta accreta who were operated on in other maternity hospitals and then referred to our tertiary center were excluded from the study.

**d. Data collection:**

We collected data about demographic parameters like age, weight, size, gestity, parity, and past history of cesarean delivery and intrauterine curettage. We also collected the clinical and biological features when admitted to the hospital like bleeding during the third trimester, transfusion during the current pregnancy (before delivery), the hemoglobin concentration, the prothrombin ratio, and platelet count.

The per-operative management including the mode of delivery, the anesthesia technique, and the surgical technique was also assessed.

The surgical technique includes the radical treatment based on total surgical removal of the placenta (hysterectomy), or conservative treatment when the placenta was left in situ and the surgeon opted for hemostatic suture techniques, arterial ligation, and medical treatment using methotrexate.

The blood loss was calculated according to the gross formula [5].

Blood loss (Gross Formula) = total blood volume of a pregnant woman (80 ml/kg) × weight (kg) ×  $[(Hb.i - Hb.d2)/((Hb.i + Hb.d2)/2)] + 500$  ml for every RBC unit transfused.

Hb.i: hemoglobin concentration before delivery.

Hb.d2: hemoglobin concentration of the second day after delivery.

To assess the impact of antenatal diagnosis of placenta accreta, we compared the blood loss, the transfusions required, the need for catecholamines, and the anesthesia and surgery-related complications. A massive transfusion was defined by the transfusion of more than 4 RBC units within the first hour or 10 RBC units within the first 24 hours after delivery. The duration of hospital stay was also compared. The neonatal outcomes including the term at delivery, the incidence of prematurity, the need for neonatal intensive care unit referral, and stillbirth were also assessed.

#### **e. Study size**

The sample size determination was based on data from the preliminary results of the 20 last patients enrolled in this study (10 with antenatal diagnosis and 10 without). The incidence of blood loss exceeding 2 L was 10 % in the antenatal diagnosis group and 80% in the second group. So, we determined that a study sample of 14 patients in each group is required for a 95% confidence level and a 5% margin of error.

#### **f. Bias:**

All patients had the same therapeutic protocol. All patients had an ultrasound examination in the third trimester of pregnancy. In the case of uncertain diagnosis of PA with ultrasounds, a MRI was done.

Patients with antenatal diagnosis of placenta accreta had elective cesarean section scheduled at the 35th or 36th gestational weeks. Special precautions were used. A multidisciplinary team, including 2 experienced obstetricians, an anesthesiologist, an interventional radiologist, a neonatologist, and in some cases, a urologist, was involved in delivery. Two red blood cell (RBC) units were ready to use in the operation room. Patients with antenatal diagnosis were operated on under general anesthesia. If placental removal failed, a cesarean hysterectomy or conservative treatment may be performed. In cases with extensive bladder involvement, when a cesarean hysterectomy was considered unsafe, a hysterectomy with bladder reconstruction and ureterostomy can be performed.

The transfusion protocol was the same for both groups (the protocol was approved by the department and the institution). The thresholds of transfusion were 7g/dL of hemoglobin, 50% of prothrombin ratio, and  $20 \times 10^6/L$  of platelet count.

As the blood loss clinical estimation (blood collection) was operator dependent, we used an objective method based on the variation of hemoglobin concentration in the first two days after delivery (Gross formula) to calculate the blood loss.

#### **g. Groups definition:**

To assess the impact of the antenatal diagnosis on maternal outcomes (Blood loss, transfusions, and maternal morbidity and mortality), the patients included were divided into two groups:

- **Group 1:** patients with antenatal diagnosis of placenta accreta according to the ultrasounds or the MRI data.
- **Group 2:** patients with an intrapartum diagnosis of placenta accreta (unexpected PA).

#### **h. Statistical analysis:**

Statistical analyses were performed using the SPSS 23.0 (SPSS, Chicago, IL, USA) statistical package. Continuous variables were presented as mean value  $\pm$  standard deviation. We distinguished two groups according to the antenatal diagnosis of placenta accreta. The comparison between groups was achieved by the Student's t-test and Chi2 test for continuous variables and categorical variables, respectively. The Fisher exact test was used when the Chi 2 test was not applicable. The Mann-Whitney U test was used for non-parametric continuous variables. A binary logistic regression analysis was done to investigate

the impact of antenatal diagnosis on maternal outcomes. Odds ratios, and a confidence interval of 95% (OR,95% CI) were reported. The significance threshold was set at  $p < 0.05$ .

#### **i. Ethical approval:**

The approval of the Hedi Chaker University Hospital Local Ethics Committee was obtained before beginning the study.

#### **Results:**

In this study, we included 57 patients with placenta accreta over 44578 deliveries during the study period. Two patients who were initially taken in charge in other hospitals and secondly referred to our center were excluded from the study. Placenta accreta was confirmed by anatomopathological examination in 53 cases (all cases treated by a hysterectomy). The incidence of placenta accreta was 0.13 % (1/782 deliveries). All patients had obstetric ultrasounds examination but placenta accreta was suspected in only 35 patients (61.4%). Of these 35 suspected patients, only 15 patients had a MRI examination. The MRI confirmed the diagnosis of placenta accreta in all cases.

Then patients were divided into the antenatal diagnosis group (group 1;  $n=35$ ) and the unexpected PA group (Group 2;  $n=22$ ).

The demographic parameters (age, weight, high) and historical characteristics (gravidity, parity, history of cesarean delivery or uterine surgery) of the women were comparable in both groups (Table 1). The current pregnancy characteristics and preoperative management were also comparable in both groups (table 2).

The antenatal diagnosis of placenta accreta reduced significantly the blood loss from  $2480 \pm 1317$  ml in group 2 to  $1610 \pm 908$  ml in group 1 with  $p=0.007$ .

Severe bleeding (blood loss superior to 2L) was more frequent in patients without antenatal diagnosis of placenta accreta (81.8% versus 5.7% when diagnosed prenatally with  $p= 0.001$  and  $OR= 2.35$ ; 95% CI:1.08- 5.62. The antenatal diagnosis of PA reduced the need for transfusion. In group 1, only 10 patients needed transfusion (28.5 %) versus 21 patients (95.4%) in group 2;  $p= 0.001$ . The risk of transfusion was higher when the placenta accreta was not diagnosed prenatally with  $OR=1.85$ ; 95%CI: 1.18- 6.1. The transfusion details are summarized in table 3.

Massive transfusion was higher in the unexpected PA group, but this difference was not statistically significant (table 3). In our study, we noted 3 cases of hemorrhagic shock that needed the administration of catecholamines peroperatively. All of them were unexpected PA. Surgical and anesthesia complications were comparable between both groups. Per and postoperative maternal complications were also comparable between both groups (table 4). For neonatal outcomes, preterm birth was more frequent when the PA was diagnosed antenatally (table 4). Expected PA was correlated with a higher risk of prematurity with  $OR= 2.04$ , 95% CI: 1.05-4.8. However, the birth weight and the incidence of referral to the NICU were comparable in both groups. Any case of stillbirth was noted in our study.

#### **Discussion**

In this study, we showed that the antenatal diagnosis of placenta accreta using ultrasounds technique and MRI allowed a significantly reduced blood loss and lower rates of transfusions requirements as a consequence. We showed also that the absence of this antenatal diagnosis was correlated with an increased risk of severe bleeding (blood loss superior to 2L) and RBC transfusion.

So, this study emphasizes the role of the antenatal diagnosis that allows planned and organized management by a multidisciplinary team and thus can reduce hemorrhagic morbidity, compared with unexpected placenta accreta [6]. Our study has a clinical implication as it emphasizes the role of prenatal ultrasound and MRI as promising diagnostic tools for PA in the third trimester, in reducing the maternal blood loss and maternal morbidity as a consequence. As a low-income country, access to healthcare structures can be difficult at times, and high-level maternity hospitals with multidisciplinary teams are not available in all regions of our country [7]. So, we still have an important group of patients who did not have a correct antenatal screening of the placenta accreta. Furthermore, patients can sometimes neglect the utility of prepartum consultations, particularly multiparous ones. This study shows that gynecologists as well as patients should be aware of the higher risk of postpartum complications due to the absence of an antenatal diagnosis of the placenta accreta [8].

The placenta accreta spectrum in our study was comparable with the literature data. The incidence was 1/782 which is near 1/1000 of recent publications [9, 10]. The main risk factors including placenta previa, previous cesarean section, uterine surgeries, in-vitro fertilization, and advanced maternal age were identified in our cases [6, 11]. Understanding placenta accreta spectrum risk factors may facilitate patient identification and may help in prenatal diagnosis. We suggest particular caution for patients at risk of abnormal placentation and we think that using advanced techniques like MRI for prenatal diagnosis seems to be reasonable [12]. MicroRNAs (miRNAs) are small non-coding RNA molecules (~22 nucleotides long) that suppress gene expression by binding to the 3' end of the untranslated region (3'-UTR) of target mRNAs [13]. It has been reported that miR-34a, miR-29a/b/c, and miR-125a are significantly down-regulated in placenta accreta but the mechanisms by which miRNAs might contribute to PAS pathogenesis have yet to be determined [14]. Nevertheless, these biomarkers demonstrated modest screening efficiency [15].

The Ultrasounds remain the primary tool in diagnosing Placenta accreta [9]. Although the increasing role of MRI in placenta accrete diagnosis is evident, it requires experienced readers [16]. The literature reveals several disparate but conceptually overlapping MRI signs. Identifying and differentiating between placenta increta and percreta on imaging may be quite challenging even with MRI and sometimes even on final pathology [12,16].

In our study ultrasound was performed in all patients but diagnosed placenta accreta in only 61.4% of cases which is lower than literature [17]. However, in a recent meta-analysis including 3209 pregnancies [17], ultrasounds had 90.6 % of sensitivity and 97.1 % of specificity for placenta accreta diagnosis. This may be explained by the operator dependence of this examination as well as his experience in managing such rare and unusual situations.

Other studies showed that prenatal MRI has an excellent diagnostic accuracy in identifying the depth and the topography of placental invasion [18], inspite of an interobserver variability [19]. This meta-analysis [18] including 20 studies with 1080 pregnancies showed a high sensibility of the MRI in diagnosing accreta (94.4%), increta (100%), percreta (86.5%) and high specificity. the corresponding values for specificity were 98.8%, 97.3% and 96.8%. These results are comparable with those of our study in which MRI diagnosed antenatally the placenta accreta in 100% of cases.

Antenatal diagnosis allows safe delivery planning and better team organization like the referral to specialized centers for placenta accreta management, which may improve the maternal and neonatal outcomes [20]. This multidisciplinary organization can lead to reduced blood loss and reduced transfusion rates and so reduced maternal morbidity [21, 22, 23]. Recent studies showed that the maternal morbidity was also correlated to other factors like

the invasion topography of the placenta [24]. Another study including 29 parturients with placenta accreta showed that MRI features may predict massive hemorrhage and may be helpful for pre-operative preparation of placenta accreta patients [25]. However, MRI features were not significant for predicting adverse neonatal events including preterm delivery, low birth weight, and 5-minute Apgar score [26].

In our study we noted a higher rate of preterm birth in expected placenta accreta patients. This may be due to the delivery planning from 35 to 36 WG to reduce the risk of severe hemorrhage. Similar results were found in previous studies [27, 28].

The main limitation of this study is the bias in the management protocol. Indeed, blood loss and transfusions may depend on the surgical procedure and particularly the rapid bleeding control [29], as well as the surgical expertise [30], which can't be the same in both groups. Our sample size was calculated on the basis of severe bleeding which resulted in a small number of patients that can't allow the comparison of maternal complications whose incidence is lower [31,32]. It was reported that during cesarean hysterectomy, the risk for urinary tract injury is less than 15% [33]. On the other hand, leaving the placenta in situ exposes women to other serious complications, such as infection, and severe bleeding [34, 35]. This is why the majority of our patients had a cesarean hysterectomy. This may be due to the advanced age and multiparity of our patients but also to the unavailability of multidisciplinary innovative approaches using Balloon catheter occlusion or arterial embolization that may reduce blood flow and potentially prevent life-threatening hemorrhage complicating conservative treatments [36, 37].

#### **Conclusion:**

The antenatal diagnosis of placenta accreta allows improved maternal outcomes. It can lead to reduced blood loss and lower rates of transfusions. Unexpected placenta accreta was correlated with an additional risk of severe bleeding and transfusion requirement. This may be due to the preoperative cautions resulting in a safe delivery planning and better team organization. However, we noted a higher incidence of planned preterm birth in patients with antenatal diagnosis of placenta accreta.

#### **Authors' contribution:**

M.K: original draft, writing

A.J: Conceptualization, Investigation, Methodology, review & editing

JH: Formal Analysis and Investigation

Y.E: Data curation, Formal Analysis and Investigation

M.D: Data curation and Investigation

K.C: Supervision, Validation, Visualization

K.K: Supervision, Validation, Visualization

**Funding:** No Funding for this study.

**Disclosure of Interests:** no competing interest for any author

**Ethical Approval:** was obtained from the HCUH (local ethics committee)

**Informed consent:** was obtained from all patients included in the study

**Data sharing:** Data available on request due to privacy/ethical restrictions

**Enhancing the quality and Transparency Of health Research:** this manuscript is conforming to the EQUATOR network guidelines.

## References:

- [1] Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. *BJOG*. 2014;121(1):62-70. doi: 10.1111/1471-0528.12405.
- [2] Morlando M, Collins S. Placenta Accreta Spectrum Disorders: Challenges, Risks, and Management Strategies. *Int J Womens Health*. 2020;12:1033-1045. doi: 10.2147/IJWH.S224191.
- [3] Di Mascio D, Cali G, D'antonio F. Updates on the management of placenta accreta spectrum. *Minerva Ginecol*. 2019 Apr;71(2):113-120. doi: 10.23736/S0026-4784.18.04333-2.
- [4] Satija B, Kumar S, Wadhwa L, Gupta T, Kohli S, Chandoke R, et al. Utility of ultrasound and magnetic resonance imaging in prenatal diagnosis of placenta accreta: A prospective study. *Indian J Radiol Imaging*. 2015;25(4):464-70. doi: 10.4103/0971-3026.169456.
- [5] Jaramillo S, Montane-Muntane M, Capitan D, Aguilar F, Vilaseca A, Blasi A, et al. Agreement of surgical blood loss estimation methods. *Transfusion*. 2019;59(2):508-515. doi: 10.1111/trf.15052. doi: 10.1111/trf.15052.
- [6] Erfani H, Fox KA, Clark SL, Rac M, Rocky Hui SK, Rezaei A, et al. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. *Am J Obstet Gynecol*. 2019;221(4):337.e1-337.e5. doi: 10.1016/j.ajog.2019.05.035.
- [7] Ghardallou M, Limam M, Khelifi A, et al. Obstetric referrals to a tertiary care maternity: a descriptive study. *Pan Afr Med J*. 2019;33:306. doi:10.11604/pamj.2019.33.306.16906
- [8] Limam M, Hachani F, El Ghardallou M, Bachraoui M, Mellouli M, Mtiraoui A, et al. Availability, utilization and quality of emergency obstetric care services in Sousse, Tunisia. *The Pan African medical journal*. 2021;38:272. doi: 10.11604/pamj.2021.38.272.17758
- [9] Di Mascio D, Cali G, D'antonio F. Updates on the management of placenta accreta spectrum. *Minerva Ginecol*. 2019 ;71(2):113-120. doi: 10.23736/S0026-4784.18.04333-2.
- [10] Carusi DA. The Placenta Accreta Spectrum: Epidemiology and Risk Factors. *Clin Obstet Gynecol*. 2018;61(4):733-742. doi: 10.1097/GRF.0000000000000391.
- [11] Jenabi E, Salimi Z, Salehi AM, Khazaei S. The environmental risk factors prior to conception associated with placenta accreta spectrum: An umbrella review. *J Gynecol Obstet Hum Reprod*. 2022;51(7):102406. doi: 10.1016/j.jogoh.2022.102406.
- [12] Kapoor H, Hanaoka M, Dawkins A, Khurana A. Review of MRI imaging for placenta accreta spectrum: Pathophysiologic insights, imaging signs, and recent developments. *Placenta*. 2021;104:31-39. doi: 10.1016/j.placenta.2020.11.004.

- [13] Chiofalo B, Laganà AS, Vaiarelli A, La Rosa VL, Rossetti D, Palmara V, et al. Do miRNAs Play a Role in Fetal Growth Restriction? A Fresh Look to a Busy Corner. *Biomed Res Int*. 2017;2017:6073167. doi: 10.1155/2017/6073167.
- [14] Yang T, Li N, Hou R, Qiao C, Liu C. Development and validation of a four-microRNA signature for placenta accreta spectrum: an integrated competing endogenous RNA network analysis. *Ann Transl Med*. 2020;8(15):919. doi: 10.21037/atm-20-1150.
- [15] Chen S, Pang D, Li Y, Zhou J, Liu Y, Yang S, et al. Serum miRNA biomarker discovery for placenta accreta spectrum. *Placenta*. 2020;101:215-220. doi: 10.1016/j.placenta.2020.09.068.
- [16] Zawaideh JP, Freeman S, Smith J, Bruining A, Sadler TJ, Carmisciano L, et al. Placental MRI: Identification of radiological features to predict placental attachment disease regardless of reader expertise. *Eur J Radiol*. 2022;149:110203. doi: 10.1016/j.ejrad.2022.110203.
- [17] Pagani G, Cali G, Acharya G, Trisch IT, Palacios-Jaraquemada J, Familiari A et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand*. 2018;97(1):25-37. doi: 10.1111/aogs.13238.
- [18] Familiari A, Liberati M, Lim P, Pagani G, Cali G, Buca D et al. Diagnostic accuracy of magnetic resonance imaging in detecting the severity of abnormal invasive placenta: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand*. 2018;97(5):507-520. doi: 10.1111/aogs.13258.
- [19] Finazzo F, D'antonio F, Masselli G, Forlani F, Palacios-Jaraquemada J, Minneci G, et al. Interobserver agreement in MRI assessment of severity of placenta accreta spectrum disorders. *Ultrasound Obstet Gynecol*. 2020;55(4):467-473. doi: 10.1002/uog.20381.
- [20] Ornaghi S, Maraschini A, Donati S; Regional Obstetric Surveillance System Working Group. Characteristics and outcomes of pregnant women with placenta accreta spectrum in Italy: A prospective population-based cohort study. *PLoS One*. 2021 Jun 4;16(6):e0252654. doi: 10.1371/journal.pone.0252654.
- [21] Tikkanen M, Paavonen J, Loukovaara M, Stefanovic V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. *Acta Obstet Gynecol Scand*. 2011;90(10):1140-6. doi: 10.1111/j.1600-0412.2011.01147.x.
- [22] Jarraya A, Kammoun M, Bouzid K, Ellouze Y, Chaabene K, Kolsi K. The impact of fresh frozen plasma versus fibrinogen concentrates on maternal outcomes in a severe postpartum hemorrhage requiring massive transfusion. *Critical Care & Shock*. 2022;25(6):301-308.
- [23] Jarraya A, Zghal J, Abidi S, Smaoui M, Kolsi K. Subarachnoid morphine versus TAP blocks for enhanced recovery after caesarean section delivery: A randomized controlled trial. *Anaesth Crit Care Pain Med*. 2016;35(6):391-393. doi: 10.1016/j.accpm.2015.10.012.
- [24] Chen X, Shan R, Song Q, Wei X, Liu W, Wang G. Placenta percreta evaluated by MRI: correlation with maternal morbidity. *Arch Gynecol Obstet*. 2020;301(3):851-857. doi: 10.1007/s00404-019-05420-5.
- [25] Zhang J, Xu H, Xin Y, Zhang C, Liu Z, Han X, et al. Assessment of the massive hemorrhage in placenta accreta spectrum with magnetic resonance imaging. *Exp Ther Med*. 2020;19(3):2367-2376. doi: 10.3892/etm.2020.8457.

- [26] Bourgioti C, Zafeiropoulou K, Fotopoulos S, Nikolaidou ME, Theodora M, Daskalakis G, et al. MRI prognosticators for adverse maternal and neonatal clinical outcome in patients at high risk for placenta accreta spectrum (PAS) disorders. *J Magn Reson Imaging*. 2019;50(2):602-618. doi: 10.1002/jmri.26592.
- [27] Golbasi H, Bayraktar B, Golbasi C, Omeroglu I, Sever B, Adiyaman D, et al. Expected Versus Unexpected Delivery for Placenta Accreta Spectrum (PAS) Disorders with Same Team in Single Tertiary Center. *Z Geburtshilfe Neonatol*. 2022 Dec;226(6):391-398. doi: 10.1055/a-1915-5832.
- [28] Bluth A, Schindelbauer A, Nitzsche K, Wimberger P, Birdir C. Placenta accreta spectrum disorders-experience of management in a German tertiary perinatal centre. *Arch Gynecol Obstet*. 2021;303(6):1451-1460. doi: 10.1007/s00404-020-05875-x.
- [29] Jarraya A, Khaled T, Kammoun M, Ameer K, Kolsi K. Golden hour for fibrinogen concentrate infusion to improve post partum hemorrhage. *Egypt J Anaesth*. 2018;34(2):73-4. doi: 10.1016/j.egja.2018.03.002
- [30] Doumouchtsis SK, Arulkumaran S. The morbidly adherent placenta: an overview of management options. *Acta Obstet Gynecol Scand*. 2010;89(9):1126-33. doi: 10.3109/00016349.2010.503869.
- [31] Anderson DJ, Liu H, Kumar D, Patel M, Kim S. Placenta Percreta Complications. *Cureus*. 2021;13(10):e18842. doi: 10.7759/cureus.18842.
- [32] Grace Tan SE, Jobling TW, Wallace EM, McNeilage LJ, Manolitsas T, Hodges RJ. Surgical management of placenta accreta: a 10-year experience. *Acta Obstet Gynecol Scand*. 2013;92(4):445-50. doi: 10.1111/aogs.12075.
- [33] Hoffman MS, Karlinski RA, Mangar D, Whiteman VE, Zweibel BR, Lockhart JL, et al. Morbidity associated with nonemergent hysterectomy for placenta accreta. *Am J Obstet Gynecol*. 2010;202:628.e1-5. doi: 10.1016/j.ajog.2010.03.021.
- [34] Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accreta. *BJOG*. 2009;116(5):648-54. doi: 10.1111/j.1471-0528.2008.02037.x.
- [35] Herzberg S, Ezra Y, Haj Yahya R, Weiniger CF, Hochler H, Kabiri D. Long-term gynecological complications after conservative treatment of placenta accreta spectrum. *Front Med (Lausanne)*. 2022;9:992215. doi: 10.3389/fmed.2022.992215.
- [36] Nieto-Calvache AJ, López-Girón MC, Quintero-Santacruz M, Bryon AM, Burgos-Luna JM, Echavarría-David MP, et al. A systematic multidisciplinary initiative may reduce the need for blood products in patients with abnormally invasive placenta. *J Matern Fetal Neonatal Med*. 2022;35(4):738-744. doi: 10.1080/14767058.2020.1731460.
- [37] Sichitiu J, El-Tani Z, Mathevet P, Desseuve D. Conservative Surgical Management of Placenta Accreta Spectrum: A Pragmatic Approach. *J Invest Surg*. 2021;34(2):172-180. doi: 10.1080/08941939.2019.1623956.

## Tables

Table 1: Demographic parameters

	Group 1 (n=35)	Group (n=22)	P value
Age (Years)	36.47 ± 3.54	34.7 ± 3.39	0.112
Weight (Kg)	75.73 ± 6.69	76.37 ± 9.37	0.817
Patients high (cm)	162 ± 11	164 ± 12	0.800
Gestivity (mean)	4.73 ± 2.37	4.47 ± 1.67	0.661
Patients with 1 gravidity	0 (0 %)	0 (0 %)	
Patients with 2 or more gravidities	35 (100%)	22 (100%)	
Parity (mean)	3.73 ± 1.79	3.63 ± 0.99	0.873
Patients with 1 parity	0 (0%)	0 (0%)	
Patients with 2 or more parities	35 (100%)	22 (100%)	
History of cesarean deliveries			
Patients with 0 cesarean delivery	0 (0%)	1 (4.5%)	
Patients with 1 cesarean delivery	6 (17%)	5 (22.7%)	0.789
Patients with 2 or more cesarean deliveries	29(82.5%)	19 (86,3%)	
Patients with History of curettage			
=0	30 (85.7%)	17 (77.2%)	
= 1	4 (11.4%)	4 (18.1%)	0.745
= 2 or > 2	1 (2.8%)	1(4.5%)	

Significant p value:  $p \leq 0.05$

**Table 2: current pregnancy characteristics and per operative management:**

	Group 1 (n=35)	Group 2 (n= 22)	P value
Placenta praevia in current pregnancy	35 (100%)	22 (100%)	1
Placenta accreta	29	21	0.259
Placenta increta	5	1	
Placenta percreta	1	0	
Preoperative hemoglobin concentration (g/dL)	11.1±1.67	11.18±1.28	0.848
Prothrombin ration (%)	94.3 ± 2.8	95.1 ± 3.1	0.745
Platelet level 10 <sup>6</sup> /mL	174 ± 31	186 ± 22	0.215
Bleeding during 3 <sup>rd</sup> trimester of pregnancy	17 (48.5%)	11 (50%)	0.892
Transfusion during pregnancy	0	0	-
Mode of delivery			0.911
- Cesarean section	35 (100%)	21 (95.4%)	
- Vaginal delivery	0 (0%)	1 (4.5%)	
Anesthesia			0.908
- General anesthesia	34 (97.1%)	21 (95.4 %)	
- Loco regional anesthesia	1 (2.8%)	1 (4.5%)	
Hysterectomy	35 (100%)	18 (81.8%)	0.558
Conservative treatment	0 (0%)	4 (18.1%)	
Uterine artery embolization	0 (0%)	0 (0%)	

Significant p value:  $p \leq 0.05$

**Table 3: Blood loss and the need of transfusion**

	Group 1 (n=35)	Group 2 (n=22)	P value OR [95% CI]
Blood loss (ml)	1610 ± 908	2480 ± 1317	<b>0.007</b>
Blood loss > 2L	2 (5.7%)	18 (81.8%)	<b>0.001</b> <b>2.35 [1.08- 5.62]</b>
Red cell unit transfused per patient	0.93±1.33	1.87±1.57	<b>0.045</b>
Patients needed RBC	10 (28.5%)	21 (95.4%)	<b>0.001</b> <b>1.85 [1.18- 6.1]</b>
Patients needed massive transfusion (>4 RBC / 1hour)	1 (2.8%)	5 (22.7%)	0.055
FFP transfused per patient	0.80±2.24	1.40±3.15	0.515
Patients needed FFP	1 (2.8%)	7 (31.8%)	0.066
Platelets transfused per patient	0	1.13 ± 3.09	0.165
Patients needed Platelets transfusion	0 (0%)	3 (13.6%)	0.084

OR: odds ratio; CI: confidence interval; RBC: red blood cells; FFP: fresh frozen plasma;  
Significant p value:  $p \leq 0.05$

**Table 4: maternal and neonatal morbidity:**

	<b>Group 1 (n=35)</b>	<b>Group 2 (n=22)</b>	<b>P value OR [95% CI]</b>
<b>Maternal outcomes</b>			
<b>Hemorrhagic chock (need for catecholamine)</b>	0 (0%)	3 (13.6%)	0,240
<b>surgical complication</b>	3 (8.5%)	3 (13,6%)	0.652
Urinary tract injury	2	2	-
Digestive tract injury	0	0	-
Postoperative infections	1	1	-
late bleeding or hematoma	0	0	-
<b>Anesthesia complication</b>	0 (0%)	0 (0%)	-
<b>Transfusion complication</b>	0 (0%)	1 (4.5%)	-
<b>duration of hospitalization (days)</b>	5,13±1,5	6±3,59	0,379
<b>Neonatal outcomes</b>			
<b>Term at delivery</b>	35.4 ± 5.1	37.3 ± 3.8	0.089
<b>Preterm delivery ≤ 37 WG</b>	31 (88.5%)	4 (18.1%)	<b>0.001</b> <b>2.04 [1.05-4.8]</b>
<b>Birth weight (g)</b>	2851 ± 345	3010 ±285	0.095
<b>Referral to the NICU</b>	32 (91.4 %)	21 (95.4%)	0.845
<b>Stillbirth</b>	0	0	-

OR: odds ratio; CI: confidence interval; WG: weeks of gestation; NICU: neonatal intensive care unit; Significant p value:  $p \leq 0.05$ .